Dual GIP and GLP-1 receptor agonist, tirzepatide (TZP), showed clinically meaningful HbA1c reduction and dose-dependent weight loss in Japanese patients with type 2 diabetes in an 8-week, Phase 1, multiple ascending dose study. Decreased appetite was the most frequently reported treatment-emergent adverse event, with nearly half of TZP-treated patients experiencing decreased appetite without nausea or vomiting. We explored the effects of TZP 5 mg, 10 mg, and 15 mg on meal intake and appetite sensation in these patients. Standardized lunch and dinner meals were provided on Days -1, 2 and 51 (700 kCal; 20% protein, 25% fat, 55% carb). Amount (%) of meals consumed were recorded. Subjective ratings of appetite sensations were measured by a 100-mm visual analogue scale for parameters of hunger, fullness, satiety, and prospective food consumption pre- and 4-5h post-meal. Meal intake decreased on Day 2 (TZP 5 mg) and dose-dependently decreased with TZP vs. PBO on Day 51 (Figure). The proportion of meal occasions with ≥50% meal leftover was 0% (PBO) and 16.7% (TZP 5 mg) on Day 2 and 0% (PBO), 13.6% (TZP 5 mg), 18.2% (TZP 10 mg) and 30.0% (TZP 15 mg) on Day 51. There was a trend in decreasing hunger and fullness scores with all TZP doses vs. PBO on Day 51. However, satiety, prospective food consumption and overall appetite scores did not differ among groups. TZP dose-dependently reduced meal intake and demonstrated a trend in decreased hunger.
K. Ohwaki: Employee; Self; Eli Lilly Japan K.K. K. Furihata: None. T. Oura: Employee; Self; Eli Lilly Japan K.K. Stock/Shareholder; Self; Eli Lilly and Company. T. Imaoka: Employee; Self; Eli Lilly Japan K.K.
Eli Lilly and Company